Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.13 -4.0%	$20.95	$10.21 ▼ $25.67	$4.33B	0.47	3.70 million shs	5.32 million shs
AXSM Axsome Therapeutics	$102.89 +1.3%	$106.70	$72.02 ▼ $139.13	$5.07B	0.47	677,064 shs	650,414 shs
NUVL Nuvalent	$75.53 -0.7%	$73.82	$55.54 ▼ $113.51	$5.42B	1.34	493,725 shs	360,890 shs
SPRY ARS Pharmaceuticals	$15.91 +7.4%	$14.34	$7.55 ▼ $18.51	$1.56B	0.84	1.31 million shs	2.73 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	-16.06%	-11.30%	-8.43%	+70.72%
AXSM Axsome Therapeutics	0.00%	-3.16%	-5.04%	-18.85%	+35.35%
NUVL Nuvalent	0.00%	-3.05%	-0.46%	-3.12%	-3.29%
SPRY ARS Pharmaceuticals	0.00%	+10.49%	+11.03%	+28.72%	+96.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.7779 of 5 stars	3.6	1.0	0.0	2.7	2.5	3.1
AXSM Axsome Therapeutics	4.6399 of 5 stars	4.5	2.0	4.5	1.3	4.2	0.6
NUVL Nuvalent	2.1941 of 5 stars	3.5	2.0	0.0	1.5	3.3	0.0
SPRY ARS Pharmaceuticals	3.2528 of 5 stars	3.6	2.0	0.0	2.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	52.60% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	67.49% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	52.92% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	94.85% Upside

Current Analyst Ratings Breakdown

Latest SPRY, NUVL, AXSM, and ADMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/7/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$200.00 ➝ $180.00
5/6/2025	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $165.00
5/6/2025	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$160.00 ➝ $162.00
4/29/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$190.00 ➝ $193.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.15	$0.54 per share	33.50	$1.48 per share	12.25
AXSM Axsome Therapeutics	$385.69M	13.14	N/A	N/A	$1.18 per share	87.19
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
SPRY ARS Pharmaceuticals	$89.15M	17.53	$0.01 per share	1,878.77	$2.64 per share	6.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.33	26.28	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.49	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)

Latest SPRY, NUVL, AXSM, and ADMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
3/20/2025	Q4 2024	SPRY ARS Pharmaceuticals	-$0.04	$0.52	+$0.56	$0.52	$15.46 million	$86.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
AXSM Axsome Therapeutics	3.48	2.03	1.96
NUVL Nuvalent	N/A	14.48	14.48
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AXSM Axsome Therapeutics	81.49%
NUVL Nuvalent	97.26%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AXSM Axsome Therapeutics	22.30%
NUVL Nuvalent	10.20%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

SPRY, NUVL, AXSM, and ADMA Headlines

Recent News About These Companies

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Average Target Price from Brokerages

June 19 at 1:47 AM | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

June 16, 2025 | marketbeat.com

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

June 15, 2025 | msn.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Still a Buy?

June 13, 2025 | marketbeat.com

Cantor Fitzgerald Predicts SPRY FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Cantor Fitzgerald Estimates SPRY FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Sells 115,987 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 6, 2025 | marketbeat.com

Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 5, 2025 | marketbeat.com

Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 3, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3% - Here's Why

May 31, 2025 | marketbeat.com

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

May 27, 2025 | globenewswire.com

Millennium Management LLC Acquires 452,532 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 26, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Wall Street Zen to Sell

May 24, 2025 | marketbeat.com

Woodline Partners LP Purchases 133,276 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 24, 2025 | marketbeat.com

Northern Trust Corp Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 24, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from Analysts

May 24, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 Shares

May 23, 2025 | insidertrades.com

Rafferty Asset Management LLC Increases Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 23, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Raised by Wexford Capital LP

May 21, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company

May 21, 2025 | marketbeat.com

FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, NUVL, AXSM, and ADMA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.13 -0.76 (-4.02%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$18.25 +0.12 (+0.66%)

As of 06/18/2025 07:58 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Axsome Therapeutics NASDAQ:AXSM

$102.89 +1.29 (+1.27%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$101.66 -1.22 (-1.19%)

As of 06/18/2025 07:31 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Nuvalent NASDAQ:NUVL

$75.53 -0.53 (-0.70%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$75.55 +0.02 (+0.03%)

As of 06/18/2025 04:39 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$15.91 +1.09 (+7.35%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.88 -0.04 (-0.22%)

As of 06/18/2025 07:30 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time